Trials / Unknown
UnknownNCT03825731
A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Hebei Yanda Ludaopei Hospital · Academic / Other
- Sex
- All
- Age
- 2 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022 CAR-T cell immunotherapy in relapsed or refractory B-ALL. The investigators plan to include 20 subjects to receive GC022 therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GC022 | GC022 is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The subjects will receive one dose of GC022 infusion. The dosage ranges from 3×10\^5 to 1×10\^7 CAR+T/Kg. |
Timeline
- Start date
- 2019-01-17
- Primary completion
- 2019-09-16
- Completion
- 2019-09-16
- First posted
- 2019-01-31
- Last updated
- 2019-01-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03825731. Inclusion in this directory is not an endorsement.